ALPINION Launches X-CUBE 90, A High-Performance Ultrasound Diagnostic System
2.3.2021 16:00:00 EET | Business Wire | Press release
ALPINION MEDICAL SYSTEMS Co., Ltd (ALPINION), a medical ultrasound professional, announced that it will launch X-CUBE 90 in March.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005348/en/
ALPINION MEDICAL SYSTEMS launches X-CUBE 90, a high-performance ultrasound diagnostic system. X-CUBE 90 provides high-resolution diagnostic images with X+ Architecture. X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. X-CUBE 90 increases data transmission capacity, data transmission speed, and data processing speed by 4, 10, and up to 14 times compared to existing products. (Photo: Business Wire)
X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. Compared to the existing models, X-CUBE 90 provides a more detailed image and comfortable user interface and thus a diagnostic environment of greater efficiency.
X-CUBE 90 applied X+ Architecture, an imaging platform independently developed by ALPINION. X+ Architecture is a premium-grade imaging platform created by combining X+ Crystal signature™, a transducer technology with high sensitivity and wideband, and the company’s cutting-edge beamforming and data processing technology, X+ FIT. With ALPINION’s unique algorithm, large-size data are swiftly reorganized, thus clear and high-resolution images are provided.
In addition, X+ FIT, a hardware technology applied to X-CUBE 90, increases data transmission capacity, data transmission speed, and data processing speed by 4, 10, and up to 14 times compared to existing products.
ALPINION applied the following new technologies to X-CUBE 90:
- X+ MicroView: The vascular imaging mode that displays micro blood flow. It clearly displays low-speed blood flow, which has not been possible with Color Doppler at the fast frame rate.
- X+ pSWE: The Point Shear Wave Elastography shows objective quantified stiffness of tissue and the reliability index of a measured result is displayed, ensuring to reduce unnecessary biopsies for patients.
- X+ Assistant: With an optimal scanning protocol registered according to the guideline formulated from practical use, keystroke time is reduced by at least 50%, thus effectively decreasing examination time.
ALPINION CEO Hyunjong Park states, “We are thrilled about the launch of the new high-performance ultrasound diagnostic system, X-CUBE 90. We will continue introducing new products that meet the expectations of healthcare providers and patients around the world.”
About ALPINION MEDICAL SYSTEMS Co., Ltd.
As a subsidiary of ILJIN Group (015860.KS), a company representing South Korea in the field of parts and materials manufacturing, ALPINION MEDICAL SYSTEMS specializes in the development and supply of medical ultrasounds. By independently developing and manufacturing high-quality transducers, diagnostic, and therapeutic ultrasound systems, it is contributing to the elevation in quality of medical services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005348/en/
Contact information
ALPINION
Selina Seo +82-2-3282-0900
marketing@alpinion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 14:00:00 EEST | Press release
Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, investigators and advocacy groups who have made this milestone possible. As we advance the GM1/GM2 study toward data readout and regulatory submission, we continue to enroll in our Phase 3 NPC study and remain focused on our goal of addressing the significant unmet medical needs faced by these rare disease communities." Professor Roberto Giugliani, Princi
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds23.7.2026 14:00:00 EEST | Press release
Francisco Partners (“FP”), a leading global investment firm that specializes in partnering with technology companies, today announced the closing of $21 billion in capital commitments across its Francisco Partners VIII, L.P. flagship fund and Francisco Partners Agility IV, L.P., its middle-market fund. FP exceeded its initial targets of $14.0 billion and $3.5 billion, respectively. This milestone builds on Francisco Partners' longstanding track record of performance, underscored by its distinction as the only firm to rank among the top three performers in each of the past six HEC-Dow Jones Large Buyout Performance Rankings.* “In our business, long-term success is created through a series of relationships built on years of trust and collaboration," said Dipanjan (“DJ”) Deb, Co-Founder and CEO of Francisco Partners. "We want to thank our investors for their support, our management teams for their dedication and performance, our friends and partners throughout the technology ecosystem, ou
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 11:21:00 EEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 10:33:00 EEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 10:00:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evotec is further streamlining these processes through one unified, easy-to-use platform that supports consistency, transpar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom